Literature DB >> 26722299

Association between serum tumor markers and metabolic tumor volume or total lesion glycolysis in patients with recurrent small cell lung cancer.

Pengyue Shi1, Xue Meng1, Mengmeng Ni1, Xindong Sun1, Ligang Xing1, Jinming Yu1.   

Abstract

The aim of the present study was to investigate the association between serum tumor markers and the metabolic tumor volume (MTV) or total lesion glycolysis (TLG), as determined by fluorine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography-computed tomography (PET/CT) in patients with recurrent small cell lung cancer (SCLC). Data from 21 patients with recurrent SCLC were collected. The levels of neuron-specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19 fragment 21-1 were measured at the time of the 18F-FDG PET/CT examination. The MTV and TLG of all lesions were calculated. Pearson correlation analyses were used to estimate the correlations between NSE level and PET findings. Pearson correlation analyses showed that NSE was the only tumor marker to have a strong correlation with MTV or TLG (r=0.787, P<0.001; r=0.866, P<0.001, respectively). In patients with a normal NSE level, no correlation was found between NSE and MTV or TLG (r=0.018, P=0.958; r=-0.003, P=0.92, respectively), but a significant correlation was found in patients with an abnormal NSE level (r=0.789, P<0.01; r=0.872, P=0.01, respectively). Therefore, TLG and MTV may serve as sensitive markers of tumor burden in patients with recurrent SCLC, with TLG showing greater sensitivity. In patients with an abnormal NSE level, a higher NSE level indicates greater MTV and TLG.

Entities:  

Keywords:  metabolic tumor volume; neuron-specific enolase; positron emission tomography; small cell lung cancer; total lesion glycolysis

Year:  2015        PMID: 26722299      PMCID: PMC4665208          DOI: 10.3892/ol.2015.3673

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  26 in total

Review 1.  Predictive and prognostic factors in small cell lung cancer: current status.

Authors:  D Yip; P G Harper
Journal:  Lung Cancer       Date:  2000-06       Impact factor: 5.705

Review 2.  Neuron specific enolase in small cell lung cancer. Clinical and biochemical evaluation.

Authors:  L G Jørgensen
Journal:  Dan Med Bull       Date:  1999-02

3.  Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer.

Authors:  Akira Ono; Tateaki Naito; Ichiro Ito; Reiko Watanabe; Takehito Shukuya; Hirotsugu Kenmotsu; Asuka Tsuya; Yukiko Nakamura; Haruyasu Murakami; Kyoichi Kaira; Toshiaki Takahashi; Toru Kameya; Takashi Nakajima; Masahiro Endo; Nobuyuki Yamamoto
Journal:  Lung Cancer       Date:  2012-01-31       Impact factor: 5.705

4.  Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.

Authors:  Shengri Liao; Bill C Penney; Kristen Wroblewski; Hao Zhang; Cassie A Simon; Rony Kampalath; Ming-Chi Shih; Naoko Shimada; Sheng Chen; Ravi Salgia; Daniel E Appelbaum; Kenji Suzuki; Chin-Tu Chen; Yonglin Pu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-23       Impact factor: 9.236

5.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

6.  Correlation between serum CEA level and metabolic volume as determined by FDG PET in postoperative patients with recurrent colorectal cancer.

Authors:  Mi Yeon Choi; Kwang Min Lee; June-Key Chung; Dong Soo Lee; Jae Min Jeong; Jae Gahb Park; Jung-Hoe Kim; Myung Chul Lee
Journal:  Ann Nucl Med       Date:  2005-04       Impact factor: 2.668

7.  Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer.

Authors:  J A Bonner; J A Sloan; K M Rowland; G G Klee; J W Kugler; J A Mailliard; M Wiesenfeld; J E Krook; A W Maksymiuk; E G Shaw; R S Marks; E A Perez
Journal:  Clin Cancer Res       Date:  2000-02       Impact factor: 12.531

8.  Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer.

Authors:  D N Carney; P J Marangos; D C Ihde; P A Bunn; M H Cohen; J D Minna; A F Gazdar
Journal:  Lancet       Date:  1982-03-13       Impact factor: 79.321

9.  Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma.

Authors:  Peng Xie; Jin-Bo Yue; Han-Xi Zhao; Xin-Dong Sun; Li Kong; Zheng Fu; Jin-Ming Yu
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-20       Impact factor: 4.553

10.  Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.

Authors:  Charles C Vu; Robert Matthews; Bong Kim; Dinko Franceschi; Thomas V Bilfinger; William H Moore
Journal:  Nucl Med Commun       Date:  2013-10       Impact factor: 1.690

View more
  4 in total

1.  Prognostic value of inflammation-based markers in advanced or metastatic neuroendocrine tumours.

Authors:  J Zou; Q Li; F Kou; Y Zhu; M Lu; J Li; Z Lu; L Shen
Journal:  Curr Oncol       Date:  2019-02-01       Impact factor: 3.677

Review 2.  Tumour burden and efficacy of immune-checkpoint inhibitors.

Authors:  Filippo G Dall'Olio; Aurélien Marabelle; Caroline Caramella; Camilo Garcia; Mihaela Aldea; Nathalie Chaput; Caroline Robert; Benjamin Besse
Journal:  Nat Rev Clin Oncol       Date:  2021-10-12       Impact factor: 66.675

3.  Combining PET/CT with serum tumor markers to improve the evaluation of histological type of suspicious lung cancers.

Authors:  Rifeng Jiang; Ximin Dong; Wenzhen Zhu; Qing Duan; Yunjing Xue; Yanxia Shen; Guopeng Zhang
Journal:  PLoS One       Date:  2017-09-06       Impact factor: 3.240

4.  Identification of a RNA-Seq based prognostic signature with five lncRNAs for lung squamous cell carcinoma.

Authors:  Rui-Xue Tang; Wen-Jie Chen; Rong-Quan He; Jiang-Hui Zeng; Liang Liang; Shi-Kang Li; Jie Ma; Dian-Zhong Luo; Gang Chen
Journal:  Oncotarget       Date:  2017-04-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.